Evidence map›Paper›PMID 33529590›Full record

ArticleAmerican journal of ophthalmology2021

Prediction of Visual Field Progression from OCT Structural Measures in Moderate to Advanced Glaucoma.

Kouros Nouri-Mahdavi, Vahid Mohammadzadeh, Alessandro Rabiolo, Kiumars Edalati, Joseph Caprioli, Siamak Yousefi

Open access · greenAbstract read
In one paragraph

Article in American journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Predicting 60-4 visual field tests using 3D facial reconstruction.The British journal of ophthalmology · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Kouros Nouri-MahdaviGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA. Electronic address: nouri-mahdavi@jsei.ucla.edu.
Vahid MohammadzadehGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA.
Alessandro RabioloGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA; Department of Ophthalmology, Gloucestershire Hospitals National Health Service Foundation Trust, Cheltenham, United Kingdom.
Kiumars EdalatiGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA.
Joseph CaprioliGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA.
Siamak YousefiDepartments of Ophthalmology and Genetics, Genomics, and Informatics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
University of California, Los Angeles · USNational Health Service · GBUniversity of Tennessee Health Science Center · US

Funding

Detection of Disease Progression in Advanced GlaucomaR01EY029792 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NOURI-MAHDAVI, KOUROS · 2020 to 2024
$1.9M
Improved Glaucoma Monitoring Using Artificial-Intelligence Enabled DashboardR21EY031725 · NEI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI YOUSEFI, SIAMAK · 2020 to 2022
$545k
A hybrid artificial intelligence framework for glaucoma monitoringR21EY030142 · NEI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ELZE, TOBIAS, YOUSEFI, SIAMAK · 2019 to 2020
$499k
NEI NIH HHS R01 EY029792NEI NIH HHS R21 EY030142NEI NIH HHS R21 EY031725
6 · The paper itself

Abstract

purposeTo test the hypothesis that visual field (VF) progression can be predicted from baseline and longitudinal optical coherence tomography (OCT) structural measurements.

designProspective cohort study.

methodsA total of 104 eyes (104 patients) with ≥3 years of follow-up and ≥5 VF examinations were enrolled. We defined VF progression based on pointwise linear regression on 24-2 VF (≥3 locations with slope less than or equal to -1.0 dB/year and P < .01). We used elastic net logistic regression (ENR) and machine learning to predict VF progression with demographics, baseline circumpapillary retinal nerve fiber layer (RNFL), macular ganglion cell/inner plexiform layer (GCIPL) thickness, and RNFL and GCIPL change rates at central 24 superpixels and 3 eccentricities, 3.4°, 5.5°, and 6.8°, from fovea and hemimaculas. Areas-under-ROC curves (AUC) were used to compare models.

resultsAverage ± SD follow-up and VF examinations were 4.5 ± 0.9 years and 8.7 ± 1.6, respectively. VF progression was detected in 23 eyes (22%). ENR selected rates of change of superotemporal RNFL sector and GCIPL change rates in 5 central superpixels and at 3.4° and 5.6° eccentricities as the best predictor subset (AUC = 0.79 ± 0.12). Best machine learning predictors consisted of baseline superior hemimacular GCIPL thickness and GCIPL change rates at 3.4° eccentricity and 3 central superpixels (AUC = 0.81 ± 0.10). Models using GCIPL-only structural variables performed better than RNFL-only models.

conclusionsVF progression can be predicted with clinically relevant accuracy from baseline and longitudinal structural data. Further refinement of proposed models would assist clinicians with timely prediction of functional glaucoma progression and clinical decision making.

Indexed as

Visual FieldsAdultAgedArea Under CurveDisease ProgressionFemaleFollow-Up StudiesGlaucoma, Open-AngleHumansIntraocular PressureMachine LearningMaleMiddle AgedNerve FibersProspective StudiesRetinal Ganglion Cells

Identifiers

PMID33529590
PMCPMC8580576
OpenAlexW3126825533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.